Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVV-01 in Advanced Solid Tumors
NCT07648472Phase 1Recruiting
- Sponsor
- Joint Biosciences Ltd.
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of OVV-01 in solid tumor (2 arms), sponsored by Joint Biosciences Ltd. Primary endpoint: Dose-limiting toxicity at 4 weeks. Started Apr 2026; status: recruiting.
02
Drugs
OVV-01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07648472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07648472.